Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Pfizer Prices $31 Billion Debt Offering to Fund Seagen Acquisition
06:47am, Wednesday, 17'th May 2023
Pfizer's acquisition of cancer-focused biotech Seagen, announced in March, would be its biggest since 2009. The deal faces risks.
Seagen (SGEN) Stock Falls 6% After Director Sells Shares
09:57am, Tuesday, 16'th May 2023
Seagen (NASDAQ: SGEN ) stock is slipping on Tuesday after one of the company's directors sold some of their shares. According to a filing with the Securities and Exchange Commission (SEC), Seagen dire
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
09:03am, Tuesday, 16'th May 2023
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotech stocks on Tuesday, with HZNP stock's crash leading the way. The post Horizon Tumbles — Taking Seagen, Prometheus W
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
10:38am, Thursday, 27'th Apr 2023
Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
09:13am, Monday, 17'th Apr 2023
Pfizer's cash deal for Seagen benefits shareholders. Seagen's pipeline of antibody-drug conjugates (ADCs) looks promising.
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
08:00am, Friday, 07'th Apr 2023
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agree
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
12:10pm, Tuesday, 04'th Apr 2023
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout
07:16pm, Wednesday, 22'nd Mar 2023
Clay Siegall, the Seagen founder who resigned last year following an arrest and allegations of domestic violence, is jumping back into the biotech world as CEO and president of Morphimmune.
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
10:45am, Wednesday, 22'nd Mar 2023
Pfizer has been loading up on acquisitions to help strengthen its growth prospects. Acquiring Seagen is a big move for the company, but Pfizer isn't done with M&A yet.
3 Dividend Contenders to Buy Now for Long-Term Gains Later
07:01am, Wednesday, 22'nd Mar 2023
Dividend contenders are a group of companies that have increased the dividend they pay to shareholders for at least 10 years up to 24 years. There are currently over 360 such companies.
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
09:15am, Sunday, 19'th Mar 2023
Pfizer's dividend has a decent yield right now, and its payout will likely grow. It'll be facing a few stiff headwinds soon, but they aren't relevant in the long term.
Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?
01:02pm, Friday, 17'th Mar 2023
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
04:46pm, Tuesday, 14'th Mar 2023
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
11:45am, Tuesday, 14'th Mar 2023
Pfizer has been a stock in search of a catalyst all year long. The drugmaker's $43 billion acquisition of Seagen probably isn't the catalyst shareholders were hoping for.
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
10:44am, Tuesday, 14'th Mar 2023
Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
